RxDoctor Payments Data

Richard Mohr, MD

Family Medicine · Florence, SCNPI 1396939393

Payments from drug & device makers

$6,741in general payments, 2019–2025

Across 470 payments — averaging $14.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$666
  • AstraZeneca$376
  • Amgen$330
  • Lilly USA, LLC$275
  • Pfizer$222
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$6,56097%
  • Education$1813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,741 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$151,889
Medicare patients
392
Services billed
2,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide149$232,743
MounjaroTirzepatide102$110,645
EliquisApixaban108$90,327
FarxigaDapagliflozin Propanediol48$61,273
TrulicityDulaglutide39$50,595
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$42,613
XareltoRivaroxaban37$29,663
EntrestoSacubitril/Valsartan28$28,536
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog31$24,240
MyrbetriqMirabegron37$23,283
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$20,283
JanuviaSitagliptin Phosphate16$18,018
Xtampza ErOxycodone Myristate12$17,924
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$17,889
JardianceEmpagliflozin13$16,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$666$232,743149 claims
Lilly USA, LLCMounjaro, Trulicity$275$161,240141 claims
PfizerEliquis$222$90,327108 claims
AstraZenecaFarxiga, Breztri Aerosphere$376$81,55667 claims
GSKTrelegy Ellipta, Anoro Ellipta$69$60,50288 claims
Johnson & JohnsonXarelto$69$29,66337 claims
NovartisEntresto$36$28,53628 claims
Astellas Pharma US IncMyrbetriq$169$23,28337 claims
Boehringer IngelheimJardiance, Pradaxa$13$21,46429 claims
MerckJanuvia$49$18,01816 claims
AbbVieLinzess$3,183$12,06119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →